OBJECTIVE:To investigate the clinical efficacy and safety of a diagnosis and treatment plan for moderate coronavirus disease 2019(COVID-19)that integrates traditional Chinese(TCM)and western medicine.METHODS:One hundr...OBJECTIVE:To investigate the clinical efficacy and safety of a diagnosis and treatment plan for moderate coronavirus disease 2019(COVID-19)that integrates traditional Chinese(TCM)and western medicine.METHODS:One hundred twenty patients with moderate COVID-19 were randomized 1∶2 to the control group(n=40)and experimental group(n=80).Both groups received conventional western medicine treatment,and the experimental group also received TCM decoction.Over a 2-week period from diagnosis,we observed the time to clinical recovery(TTCR),rate of improvement on lung computed tomography(CT)imaging,time to defervescence,cough remission time,hospital discharge rate,average hospitalization stay,modified Medical Research Council(m MRC)scale score,clinical cure rate,laboratory findings,incidence of progression to severe or critical disease,and adverse events.RESULTS:Among 120 enrolled patients,108 completed the study.The baseline data did not differ between the experimental and control groups(all P>0.05).After treatment,the TTCR,rate of lung CT imaging improvement,time to defervescence,cough remission time,hospital discharge rate,average hospitalization stay(among discharged patients),m MRC scale score,clinical cure rate,and rates of normal values for laboratory findings were better in the experimental group than in the control group(P<0.05 or<0.01).The incidence of progression to severe or critical disease and the incidence of adverse events did not differ between the two groups(P>0.05).CONCLUSION:The diagnosis and treatment plan integrating Chinese and western medicine showed improved clinical efficacy compared with western medicine alone for patients with moderate COVID-19 and is worthy of clinical promotion and application.展开更多
BACKGROUND Congenital factor VII deficiency(FVIID)is a rare autosomal recessive genetic disorder.The clinical manifestations of this deficiency vary greatly.Predicting the risk of bleeding during and after childbirth ...BACKGROUND Congenital factor VII deficiency(FVIID)is a rare autosomal recessive genetic disorder.The clinical manifestations of this deficiency vary greatly.Predicting the risk of bleeding during and after childbirth of pregnant women with congenital FVIID is difficult.Recombinant factor VIIa is the most common replacement therapy for FVIID.However,no unified diagnosis and treatment plan for pregnant women with congenital FVIID has been established.CASE SUMMARY We report the clinical history of a pregnant woman who was considered to have congenital FVIID.Recombinant factor VIIa was prophylactically administered to the pregnant woman at the time of cervical fully opening.She successfully delivered a live infant without any complications,such as postpartum hemorrhage,neonatal abnormalities,and so on.CONCLUSION Prophylaxis of recombinant factor VIIa during delivery can effectively reduce the incidence of postpartum hemorrhage among pregnant women with congenital FVIID associated with a high risk of bleeding.展开更多
BACKGROUND Clear aligners have been widely used to treat malocclusions from crowding,extraction cases to orthodontic-orthognathic cases,and practitioners are exploring the border of it.For the first time,clear aligner...BACKGROUND Clear aligners have been widely used to treat malocclusions from crowding,extraction cases to orthodontic-orthognathic cases,and practitioners are exploring the border of it.For the first time,clear aligners were used to early intervene anterior cross-bite and facial asymmetry.CASE SUMMARY This case report described a four-year-old child presented with anterior cross-bite and facial asymmetry associated with functional mandibular shift,who had undergone a failed treatment with conventional appliances.The total treatment time was 18 weeks,and a stable outcome was obtained.CONCLUSION The increasing need in early treatment highlights the need for clinicians to thoroughly investigate for the patient regarding clinical manifestation as well as patient compliance.We hope that our case will be contemplated by clinicians when seeking for treatment alternatives.展开更多
Objective: To analyze the prescription law of TCM compound in the treatment of new coronavirus pneumonia, and provides reference for the clinical treatment of new coronavirus pneumonia. Methods: Collected Collected 24...Objective: To analyze the prescription law of TCM compound in the treatment of new coronavirus pneumonia, and provides reference for the clinical treatment of new coronavirus pneumonia. Methods: Collected Collected 24 novel coronavirus pneumonia related diagnostic and therapeutic plans issued by the National Health Council and the Chinese medicine authority from January 26, 2020 to March 8th ,the filtered solution involved in the formula, establishing database of traditional Chinese medicine compound prescription for the treatment of new crown pneumonia, the frequency of using frequency analysis methods of analysis and clustering analysis and association rules analysis to sort out data mining analysis of traditional Chinese medicine compound. Results: In this study, a total of 159 TCM compounds were included in the treatment of new crown pneumonia from the country and 23 provinces, municipalities and autonomous regions, involving 189 TCM compounds. A total of 62 high-frequency traditional Chinese medicines (frequency ≥ 11) were obtained, mainly including licorice, almond, ephedra, gypsum, Poria cocos, Huoxiang, etc The drug types are mainly heat-clearing drugs, vacuous drugs, moisture-curing drugs, and surfactant drugs. The main effect of the medicine was warm, cold, lukewarm and flat, the main effect of the medicine was bitter and bitter, and the main effect of the medicine was the lung, stomach and spleen. Cluster analysis results according to the performance of traditional Chinese medicine treatment of new crown pneumonia high frequency drugs into 7 classes;Association rule analysis results in 29 common drug pairs. Conclusion: In the treatment of pneumonia caused by new coronavirus infection with traditional Chinese medicine, the following characteristics are presented: the number of times of supplementing qi and Yin is more than that of attacking evil and maintaining health;The method of dispersing and solving the attack of wet, beneficial, wet, permeable and wet medicine fully embodies a variety of ways to drive away evil;In terms of drugs, heat-clearing drugs, deficiency drugs, dampness drugs and surface drugs are the main ones, highlighting that the basic treatment method is to dissolve dampness and detoxify, and replenish qi and Yin. In summary, this study can provide reference for guiding clinical drug use and developing new drugs.展开更多
基金Supported by the National Key R&D Program“Public Security Risk Prevention and Control and Emergency Technology and Equipment”Key Special Project(2020YFC0841600)Hubei Provincial Department of Science and Technology,2020 Hubei Province New Pneumonia Emergency Science and Technology Project(2020FCA027)+2 种基金Hubei Provincial Health Commission,2021-2022 TCM Scientific Research Project Key Project(ZY2021Z003)Hubei Provincial Health Commission Key Support Projects from 2021 to 2022(WJ2021Z009)Hubei Provincial Department of Science and Technology,2020 Hubei Province Key R&D Program Project(2020BCB012)。
文摘OBJECTIVE:To investigate the clinical efficacy and safety of a diagnosis and treatment plan for moderate coronavirus disease 2019(COVID-19)that integrates traditional Chinese(TCM)and western medicine.METHODS:One hundred twenty patients with moderate COVID-19 were randomized 1∶2 to the control group(n=40)and experimental group(n=80).Both groups received conventional western medicine treatment,and the experimental group also received TCM decoction.Over a 2-week period from diagnosis,we observed the time to clinical recovery(TTCR),rate of improvement on lung computed tomography(CT)imaging,time to defervescence,cough remission time,hospital discharge rate,average hospitalization stay,modified Medical Research Council(m MRC)scale score,clinical cure rate,laboratory findings,incidence of progression to severe or critical disease,and adverse events.RESULTS:Among 120 enrolled patients,108 completed the study.The baseline data did not differ between the experimental and control groups(all P>0.05).After treatment,the TTCR,rate of lung CT imaging improvement,time to defervescence,cough remission time,hospital discharge rate,average hospitalization stay(among discharged patients),m MRC scale score,clinical cure rate,and rates of normal values for laboratory findings were better in the experimental group than in the control group(P<0.05 or<0.01).The incidence of progression to severe or critical disease and the incidence of adverse events did not differ between the two groups(P>0.05).CONCLUSION:The diagnosis and treatment plan integrating Chinese and western medicine showed improved clinical efficacy compared with western medicine alone for patients with moderate COVID-19 and is worthy of clinical promotion and application.
基金Supported by Natural Science Foundation of Guangxi,No.2018JJB140171Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University(2020)+1 种基金Development and Application of Appropriate Medical and Health Technologies in Guangxi,No.S2018111Self-funded Scientific Research Project of Guangxi Health Commission,No.Z20190512.
文摘BACKGROUND Congenital factor VII deficiency(FVIID)is a rare autosomal recessive genetic disorder.The clinical manifestations of this deficiency vary greatly.Predicting the risk of bleeding during and after childbirth of pregnant women with congenital FVIID is difficult.Recombinant factor VIIa is the most common replacement therapy for FVIID.However,no unified diagnosis and treatment plan for pregnant women with congenital FVIID has been established.CASE SUMMARY We report the clinical history of a pregnant woman who was considered to have congenital FVIID.Recombinant factor VIIa was prophylactically administered to the pregnant woman at the time of cervical fully opening.She successfully delivered a live infant without any complications,such as postpartum hemorrhage,neonatal abnormalities,and so on.CONCLUSION Prophylaxis of recombinant factor VIIa during delivery can effectively reduce the incidence of postpartum hemorrhage among pregnant women with congenital FVIID associated with a high risk of bleeding.
基金Supported by National Nature Science Foundation of China,No.31670992,and No.31271052.
文摘BACKGROUND Clear aligners have been widely used to treat malocclusions from crowding,extraction cases to orthodontic-orthognathic cases,and practitioners are exploring the border of it.For the first time,clear aligners were used to early intervene anterior cross-bite and facial asymmetry.CASE SUMMARY This case report described a four-year-old child presented with anterior cross-bite and facial asymmetry associated with functional mandibular shift,who had undergone a failed treatment with conventional appliances.The total treatment time was 18 weeks,and a stable outcome was obtained.CONCLUSION The increasing need in early treatment highlights the need for clinicians to thoroughly investigate for the patient regarding clinical manifestation as well as patient compliance.We hope that our case will be contemplated by clinicians when seeking for treatment alternatives.
基金High level innovation and entrepreneurship team of Liaoning Province(No.XLYC1808011)
文摘Objective: To analyze the prescription law of TCM compound in the treatment of new coronavirus pneumonia, and provides reference for the clinical treatment of new coronavirus pneumonia. Methods: Collected Collected 24 novel coronavirus pneumonia related diagnostic and therapeutic plans issued by the National Health Council and the Chinese medicine authority from January 26, 2020 to March 8th ,the filtered solution involved in the formula, establishing database of traditional Chinese medicine compound prescription for the treatment of new crown pneumonia, the frequency of using frequency analysis methods of analysis and clustering analysis and association rules analysis to sort out data mining analysis of traditional Chinese medicine compound. Results: In this study, a total of 159 TCM compounds were included in the treatment of new crown pneumonia from the country and 23 provinces, municipalities and autonomous regions, involving 189 TCM compounds. A total of 62 high-frequency traditional Chinese medicines (frequency ≥ 11) were obtained, mainly including licorice, almond, ephedra, gypsum, Poria cocos, Huoxiang, etc The drug types are mainly heat-clearing drugs, vacuous drugs, moisture-curing drugs, and surfactant drugs. The main effect of the medicine was warm, cold, lukewarm and flat, the main effect of the medicine was bitter and bitter, and the main effect of the medicine was the lung, stomach and spleen. Cluster analysis results according to the performance of traditional Chinese medicine treatment of new crown pneumonia high frequency drugs into 7 classes;Association rule analysis results in 29 common drug pairs. Conclusion: In the treatment of pneumonia caused by new coronavirus infection with traditional Chinese medicine, the following characteristics are presented: the number of times of supplementing qi and Yin is more than that of attacking evil and maintaining health;The method of dispersing and solving the attack of wet, beneficial, wet, permeable and wet medicine fully embodies a variety of ways to drive away evil;In terms of drugs, heat-clearing drugs, deficiency drugs, dampness drugs and surface drugs are the main ones, highlighting that the basic treatment method is to dissolve dampness and detoxify, and replenish qi and Yin. In summary, this study can provide reference for guiding clinical drug use and developing new drugs.